Seleniun/cancer claim
This article was originally published in The Tan Sheet
Executive Summary
Supplement maker Wellness Lifestyles d/b/a American Longevity seeks FDA approval of health claims stating selenium "may reduce the risk of certain cancers" and "may produce anticarcinogenic effects in the body." Petition filed July 10 notes claims "do not identify specific intake quantities for selenium," although studies have shown risk reduction with 50-200 mcg/day. Adult daily intake below 900 mcg "is unlikely to cause adverse reactions," Wellness adds. Petition cites six human clinical trials (three in China, and one each in U.S., India, Italy) on selenium supplementation and cancer incidence. Firm is represented by Emord & Associates (Washington, D.C.), which filed a health claim petition for phosphatidylserine and cognitive dysfunction/dementia in April (1"The Tan Sheet" May 6, 2002, p. 10)...
You may also be interested in...
Phosphatidylserine, Dementia, Cognitive Decline Health Claim Sought
No particular dose of phosphatidylserine works better at reducing the severity of cognitive dysfunction and the risk of dementia, according to a health claim petition filed with FDA April 19
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.